Esophagogastric cancer: Integration of targeted therapies into systemic chemotherapy

Current Cancer Drug Targets

Volumn 11, Issue 6, 2011, Pages 681-687

  Moehler, M ^a   Schwarz, S ^a   Wagner, A D ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Bevacizumab; Cetuximab; Gastric cancer; Multi tyrosine kinase inhibitors

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CAPECITABINE; CATUMAXOMAB; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GAMMA GLUTAMYLTRANSFERASE; GEFITINIB; IRINOTECAN; LAPATINIB; MATUZUMAB; MONOCLONAL ANTIBODY; OXALIPLATIN; PANITUMUMAB; PLACEBO; SORAFENIB; SUNITINIB; TRASTUZUMAB;

ADD ON THERAPY; ADVANCED CANCER; ANEMIA; ANOREXIA; ASTHENIA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; ESOPHAGOGASTRIC CANCER; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPONATREMIA; INTESTINE PERFORATION; LYMPHOCYTOPENIA; METASTASIS; MOLECULARLY TARGETED THERAPY; NAUSEA; NEUTROPENIA; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; SKIN TOXICITY; STOMACH CANCER; UNSPECIFIED SIDE EFFECT; VEIN THROMBOSIS;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; ESOPHAGEAL NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 79960032149     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800911796191006     Document Type: Review

References (34)

1. Field, K.; Michael, M.; Leong, T. Locally advanced and metastatic gastric cancer: current management and new treatment developments. Drugs 2008, 68, 299-317.
2. Wagner, A. D.; Unverzagt, S.; Grothe, W.; Kleber, G.; Grothey, A.; Haerting, J.; Fleig, W. E. Chemotherapy for advanced gastric cancer. Cochrane Database Syst. Rev. 2010, 3, CD004064.
3. Cunningham, D.; Allum, W.H.; Stenning S.P.; Thompson, J. N.; Van de Velde, C. J.; Nicolson, M.; Scarffe, J. H.; Lofts, F. J.; Falk, S. J.; Iveson, T. J.; Smith, D. B.; Langley, R. E.; Verma, M.; Weeden, S.; Chua, Y. J. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 2006, 355, 11-20.
4. Ychou, M.; Boige, V.; Pignon, J.P.; Conroy, T.; Bouché, O.; Lebreton, G.; Ducourtieux, M.; Bedenne, L.; Fabre, J.M.; Saint-Aubert, B.; Genève, J.; Lasser, P.; Rougier, P. Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: A FNCLCC and FFCD Multicenter Phase III Trial. J. Clin. Oncol. 2011, 29, 1715-1721
5. Wagner, A. D.; Moehler, M. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era. Curr. Opin. Oncol. 2009, 21, 381-385
6. Lauren, P. The Two Histological Main Types of Gastric Carcinoma: Diffuse and So-Called Intestinal-Type Carcinoma. An Attempt at a Histo-Clinical Classification. Acta Pathol. Microbiol. Scand. 1965, 64, 31-49.
7. Cervantes, A.; Rodriguez Braun, E.; Perez Fidalgo, A.; Chirivella Gonzalez, I. Molecular biology of gastric cancer. Clin. Transl. Oncol. 2007, 9, 208-15.
8. Dragovich, T.; McCoy, S.; Fenoglio-Preiser, C. M.; Wang, J.; Benedetti, J. K.; Baker, A. F.; Hackett, C. B.; Urba, S. G.; Zaner, K. S.; Blanke, C. D.; Abbruzzese, J. L. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J. Clin. Oncol. 2006, 24, 4922-4927.
9. Hofmann, M.; Stoss, O.; Shi, D.; Buttner, R.; van de Vijver, M.; Kim, W.; Ochiai, A.; Ruschoff, J.; Henkel, T. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52: 797-805.
10. Tokunaga, A.; Onda, M.; Okuda, T.; Teramoto, T.; Fujita, I.; Mizutani, T.; Kiyama, T.; Yoshiyuki, T.; Nishi, K.; Matsukura, N. Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. Cancer 1995, 75, 1418-1425.
11. Drescher, D.; Moehler, M.; Gockel, I.; Frerichs, K.; Muller, A.; Dunschede, F.; Borschitz, T.; Biesterfeld, S.; Holtmann, M.; Wehler, T.; Teufel, A.; Herzer, K.; Fischer, T.; Berger, M. R.; Junginger, T.; Galle, P. R.; Schimanski, C. C. Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma-a rationale for a molecular targeting strategy? World J. Gastroenterol. 2007, 13, 3605-3609.
12. Tabernero, J.; Macarulla, T.; Ramos, F. J.; Baselga, J. Novel targeted therapies in the treatment of gastric and esophageal cancer. Ann. Oncol. 2005, 16, 1740-1748.
13. Ferry, D. R.; Anderson, M.; Beddard, K.; Tomlinson, S.; Atherfold, P.; Obszynska, J.; Harrison, R.; Jankowski, J. A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin. Cancer Res. 2007, 13, 5869-5875.
14. Pinto, C.; Di Fabio, F.; Siena, S.; Cascinu, S.; Rojas Llimpe, F. L.; Ceccarelli, C.; Mutri, V.; Giannetta, L.; Giaquinta, S.; Funaioli, C.; Berardi, R.; Longobardi, C.; Piana, E.; Martoni, A. A. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann. Oncol. 2007, 18, 510-517.
15. Han, S. W.; Oh, D. Y.; Im, S. A.; Park, S. R.; Lee, K. W.; Song, H. S.; Lee, N. S.; Lee, K. H.; Choi, I. S.; Lee, M. H.; Kim, M. A.; Kim, W. H.; Bang, Y. J.; Kim, T. Y. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br. J. Cancer 2009, 100, 298-304.
16. Lordick, F.; Luber, B.; Lorenzen, S.; Hegewisch-Becker, S.; Folprecht, G.; Woll, E.; Decker, T.; Endlicher, E.; Rothling, N.; Schuster, T.; Keller, G.; Fend, F.; Peschel, C. Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br. J. Cancer 2010, 102, 500-505.
17. Moehler, M.; Mueller, A.; Trarbach, T.; Lordick, F.; Seufferlein, T.; Kubicka, S.; Geissler, M.; Schwarz, S.; Galle, P. R.; Kanzler, S. Cetuximab with irinotecan, folinic acid and 5-fluorouracil as firstline treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Ann. Oncol. 2010, doi: 10.1093/annonc/mdq591
18. Kim, C.; Lee, J. L.; Ryu, M. H.; Chang, H. M.; Kim, T. W.; Lim, H. Y.; Kang, H. J.; Park, Y. S.; Ryoo, B. Y.; Kang, Y. K. A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Invest. New Drugs 2011, 29(2):366-73
19. Pinto, C.; Di Fabio, F.; Barone, C.; Siena, S.; Falcone, A.; Cascinu, S.; Rojas Llimpe, F. L.; Stella, G.; Schinzari, G.; Artale, S.; Mutri, V.; Giaquinta, S.; Giannetta, L.; Bardelli, A.; Martoni, A. A.Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br. J. Cancer 2009, 101, 1261-1268.
20. Cunningham, D.; Starling, N.; Rao, S.; Iveson, T.; Nicolson, M.; Coxon, F.; Middleton, G.; Daniel, F.; Oates, J.; Norman, A. R. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 2008, 358, 36-46.
21. Rao, S.; Starling, N.; Cunningham, D.; Benson, M.; Wotherspoon, A.; Lupfert, C.; Kurek, R.; Oates, J.; Baselga, J.; Hill, A. Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. Br. J. Cancer 2008, 99, 868-874.
22. Ellis, L. M.; Hicklin, D. J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 2008, 8, 579-591.
23. Maeda, K.; Chung, Y. S.; Ogawa, Y.; Takatsuka, S.; Kang, S. M.; Ogawa, M.; Sawada, T.; Sowa, M. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996, 77, 858-863.
24. Shah, M. A.; Ramanathan, R. K.; Ilson, D. H.; Levnor, A.; D'Adamo, D.; O'Reilly, E.; Tse, A.; Trocola, R.; Schwartz, L.; Capanu, M.; Schwartz, G. K.; Kelsen, D. P. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J. Clin. Oncol. 2006, 24, 5201-5206.
25. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350, 2335-2342.
26. Nalluri, S. R.; Chu, D.; Keresztes, R.; Zhu, X.; Wu, S. Risk ofvenous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008, 300, 2277-2285.
27. Scappaticci, F. A.; Skillings, J. R.; Holden, S. N.; Gerber, H. P.; Miller, K.; Kabbinavar, F.; Bergsland, E.; Ngai, J.; Holmgren, E.; Wang, J.; Hurwitz, H. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J. Natl. Cancer Inst. 2007, 99, 1232-1239.
28. Bang, Y. J.; Kang, Y. K.; Kang, W. K.; Boku, N.; Chung, H. C.; Chen, J. S.; Doi, T.; Sun, Y.; Shen, L.; Qin, S.; Ng, W. T.; Tursi, J. M.; Lechuga, M. J.; Lu, D. R.; Ruiz-Garcia, A.; Sobrero, A. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest. New Drugs 2010, DOI: 10.1007/s10637-010-9438-y
29. Sun, W.; Powell, M.; O'Dwyer, P. J.; Catalano, P.; Ansari, R. H.; Benson, A. B., 3rd Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J. Clin. Oncol. 2010, 28, 2947-2951.
30. Heiss, M. M.; Murawa, P.; Koralewski, P.; Kutarska, E.; Kolesnik, O. O.; Ivanchenko, V. V.; Dudnichenko, A. S.; Aleknaviciene, B.; Razbadauskas, A.; Gore, M.; Ganea-Motan, E.; Ciuleanu, T.; Wimberger, P.; Schmittel, A.; Schmalfeldt, B.; Burges, A.; Bokemeyer, C.; Lindhofer, H.; Lahr, A.; Parsons, S. L. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int. J. Cancer 2010, 127, 2209-2221.
31. Doi, T.; Muro, K.; Boku, N.; Yamada, Y.; Nishina, T.; Takiuchi, H.; Komatsu, Y.; Hamamoto, Y.; Ohno, N.; Fujita, Y.; Robson, M.; Ohtsu, A. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J. Clin. Oncol. 2010, 28, 1904-1910.
32. Ratain, M. J.; Sargent, D. J. Optimising the design of phase II oncology trials: the importance of randomisation. Eur. J. Cancer 2009, 45, 275-280.
33. Al-Batran, S. E.; Hartmann, J. T.; Hofheinz, R.; Homann, N.; Rethwisch, V.; Probst, S.; Stoehlmacher, J.; Clemens, M. R.; Mahlberg, R.; Fritz, M.; Seipelt, G.; Sievert, M.; Pauligk, C.; Atmaca, A.; Jager, E. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann. Oncol. 2008, 19: 1882-1887.
34. Moehler, M.; Al-Batran, S.-E.; Andus, T.; Anthuber, M.; Arends, J.; Arnold, D.; Aust, D.; Baier, P.; Baretton, G.; Bernhardt, J.; Boeing, H.; Böhle, E.; Bokemeyer, C.; Bornschein, J.; Budach, W.; Burmester, E.; Caca, K.; Diemer, W. A.; Dietrich, C. F.; Ebert, M.; Eickhoff, A.; Ell, C.; Fahlke, J.; Feußner, H.; Fietkau, R.; Fischbach, W.; Fleig, W.; Flentje, M.; Gabbert, H. E.; Galle, P. R.; Geissler, M.; Gockel, I.; Graeven, U.; Grenacher, L.; Groß, S.; Hartmann, J. T.; Heike, M.; Heinemann, V.; Herbst, B.; Herrmann, T.; Höcht, S.; Hofheinz, R. D.; Höfler, H.; Höhler, T.; Hölscher, A. H.; Horneber, M.; Hübner, J.; Izbicki, J. R.; Jakobs, R.; Jenssen, C.; Kanzler, S.; Keller, M.; Kiesslich, R.; Klautke, G.; Körber, J.; Krause, B. J.; Kuhn, C.; Kullmann, F.; Lang, H.; Link, H.; Lordick, F.; Ludwig, K.; Lutz, M.; Mahlberg, R.; Malfertheiner, P.; Merkel, S.; Messmann, H.; Meyer, H.-J.; Mönig, S.; Piso, P.; Pistorius, S.; Porschen, R.; Rabenstein, T.; Reichardt, P.; Ridwelski, K.; Röcken, C.; Roetzer, I.; Rohr, P.; Schepp, W.; Schlag, P. M.; Schmid, R. M.; Schmidberger, H.; Schmiegel, W.-H.; Schmoll, H.-J.; Schuch, G.; Schuhmacher, C.; Schütte, K.; Schwenk, W.; Selgrad, M.; Sendler, A.; Seraphin, J.; Seufferlein, T.; Stahl, M.; Stein, H.; Stoll, C.; Stuschke, M.; Tannapfel, A.; Tholen, R.; Thuss-Patience, P.; Treml, K.; Vanhoefer, U.; Vieth, M.; Vogelsang, H.; Wagner, D.; Wedding, U.; Weimann, A.; Wilke, H.; Wittekind, C. Und die Mitglieder der Autorengruppe. S3-Leitlinie "Magenkarzinom"- Diagnostik und Therapie der Adenokarzinome des Magens und ösophagogastralen Übergangs (AWMF-Regist.-Nr. 032-009-OL). Z Gastroenterol. 2011, 49, 461-531.